CJC-1295 no DAC + Ipamorelin dosage chart

10 mg Blend

The CJC-1295 NO DAC + Ipamorelin peptide blend is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
Dosing schedule: 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)

WEEK	DAILY DOSE (MCG EACH)	UNITS (PER INJECTION) (ML)
Weeks 1–2	100 mcg each	3 units (0.03 mL)
Weeks 3–4	150 mcg each	4.5 units (0.045 mL)
Weeks 5–6	200 mcg each	6 units (0.06 mL)
Weeks 7–12	250–300 mcg each	7.5–9 units (0.075–0.09 mL)

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl/roll until dissolved (do not shake).
4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Cycle & Timing

This protocol runs on a 5 days on / 2 days off cycle.

Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
Keep the dose time consistent on dosing days.
If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 100–300 mcg of each peptide daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
Target: 200–300 mcg each peptide daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Typically before bed or upon waking; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
For doses under 10 units, use 30- or 50-unit syringes for better precision.

How This Works

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
Some individuals report increased appetite, water retention, or tingling sensations.

Lifestyle Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep quality, as GH is predominantly released during deep sleep.
Manage stress to support optimal hormonal balance and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies needed

Plan covers the full 12-week protocol at the lowest listed starting dose: 0.1 mg per dose, 5 days on / 2 days off (60 administrations in total), using 10 mg vials. After mixing with 3 mL, the concentration is 3.33 mg/mL and each dose requires 0.03 mL total.

CJC-1295 no DAC + Ipamorelin vials (10 mg Blend each)

Vials are rounded up only after calculating the whole protocol: ceil(6 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (12 weeks): 1 vial (6 mg needed ÷ 10 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (12 weeks): 60 syringes

Bacteriostatic water (10 mL bottles)

Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).

Full protocol (12 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.

Full protocol (12 weeks): 120 swabs

Supply	Full protocol (12 weeks)
CJC-1295 no DAC + Ipamorelin vials (10 mg Blend each)Vials are rounded up only after calculating the whole protocol: ceil(6 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.	1 vial (6 mg needed ÷ 10 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	60 syringes
Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 2 × 100-count boxes.	120 swabs

CJC-1295 no DAC + Ipamorelin dosage FAQs

How much bacteriostatic water do you use to reconstitute CJC-1295 no DAC + Ipamorelin?

Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide). for a 10 mg Blend vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

How often is CJC-1295 no DAC + Ipamorelin administered in research protocols?

Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).

What does the CJC-1295 no DAC + Ipamorelin standard / gradual approach (3 ml = ~3.33 mg/ml total) look like?

Weeks 1–2 — 100 mcg each — 3 units (0.03 mL); Weeks 3–4 — 150 mcg each — 4.5 units (0.045 mL); Weeks 5–6 — 200 mcg each — 6 units (0.06 mL); Weeks 7–12 — 250–300 mcg each — 7.5–9 units (0.075–0.09 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for CJC-1295 no DAC + Ipamorelin?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).

How should reconstituted CJC-1295 no DAC + Ipamorelin be stored?

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..

How many insulin syringe units equal a CJC-1295 no DAC + Ipamorelin dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is CJC-1295 no DAC + Ipamorelin approved for human use?

No. CJC-1295 no DAC + Ipamorelin is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.